title: Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents.
abstract: This study aims to evaluate the effects of some probiotics on sonographic and biochemical nonalcoholic fatty liver disease (NAFLD).
  
  
  
  This randomized triple-blind trial was conducted among 64 obese children with sonographic NAFLD. They were randomly allocated to receive probiotic capsule (containing Lactobacillus acidophilus ATCC B3208, 3 × 10 colony forming units [CFU]; Bifidobacterium lactis DSMZ 32269, 6 × 10 CFU; Bifidobacterium bifidum ATCC SD6576, 2 × 10 CFU; Lactobacillus rhamnosus DSMZ 21690, 2 × 10 CFU) or placebo for 12 weeks.
  
  
  
  After intervention, in the probiotic group the mean levels of alanine aminotransferase decreased from 32.8 (19.6) to 23.1 (9.9) U/L (P = 0.02) and mean aspartate aminotransferase decreased from 32.2 (15.7) to 24.3 (7.7) U/L (P = 0.02). Likewise the mean cholesterol, low-density lipoprotein-C, and triglycerides as well as waist circumference decreased in the intervention group, without significant change in weight, body mass index, and body mass index z score. After the trial, normal liver sonography was reported in 17 (53.1%) and 5 (16.5%) of patients in the intervention and placebo groups, respectively.
  
  
  
  The present findings suggest that a course of the abovementioned probiotic compound can be effective in improving pediatric NAFLD.
authors.affiliation: Pediatrics Department, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Famouri
authors.forename: Zainab
authors.initials: Z
authors.lastname: Shariat
authors.forename: Mahin
authors.initials: M
authors.lastname: Hashemipour
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Keikha
authors.forename: Roya
authors.initials: R
authors.lastname: Kelishadi
mesh_terms: D000293:Adolescent; D001644:Bifidobacterium; D015415:Biomarkers / Q000097:blood; D002648:Child; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007779:Lactobacillus acidophilus; D052201:Lacticaseibacillus rhamnosus; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D063766:Pediatric Obesity / Q000150:complications*; D019936:Probiotics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers